Experts Say Interpretable Results Unlikely In Burzynski’s Antineoplastons Studies
Special Report: Politicla Pressure, System Loopholes, Enabled Burzynski To Avoid Usuals
Scientific Process
“Unfortunate Result Of Burzynski’s Practice Over Two Decades: Thousands Of Patients, Not Enough Data” To Determine Safety, Efficacy, FDA Says
Reviewers Note Major Flaws In Design Of Burzynski’s Trials
Interview: Burzynski Explains Why He Calls Treatment “Non-Toxic”
Case Study: The Post-Surgical Treatment Of A Child With Medulloblastoma At The Burzynski Clinic
Trending Stories
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors
- KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures









